San Diego, United States
Function Oncology, founded in 2019 and headquartered in the United States, is revolutionizing the biotechnology and health sectors with its personalized approach to functional genomics in cancer research.
The company's slogan, "Personalized functional genomics transforming the future of cancer," encapsulates its mission to use a CRISPR-powered platform to delve deeper than traditional gene sequencing. By focusing on the function of genes, Function Oncology is poised to uncover bespoke therapeutic opportunities and spearhead the development of targeted cancer therapies.
Securing a $28.00M Series A investment on April 12, 2023, from notable investors such as Casdin Capital, Andreessen Horowitz (a16z), Alexandria Venture Investments, and Section 32, the company demonstrates strong financial backing and investor confidence.
With its innovative approach and substantial support, Function Oncology is well-positioned to drive significant advancements in precision medicine.
